This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bateman, H Articles by Paget, S A Search for Related Content PubMed PubMed Citation Articles by Bateman, H Articles by Paget, S A Social Bookmarking                         What's this?

Increased cervical dysplasia in intravenous cyclophosphamidetreated patients with SLE: a preliminary study

Y Yazici

Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA; Hospital for Special Surgery, 535 East 70th Street, 7th Floor, New York, NY 10021, USA Tel: (+ 1) 212 606 1845; Fax: (+ 1) 212 606 1170 yaziciy{at}hss.edu

L Leff

M Peterson

S A Paget

Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA

To determine if intravenous cyclophosphamide (IV-C) causes an excess of cervical dysplasia and/or cancer in systemic lupus erythematosus (SLE) patients, a retrospective review was conducted. Patients with SLE who received IV-C between 1988–98 (study group) were compared with a group of SLE patients who had not received IV-C (control group).

Of the 79 IV-C-treated SLE patients identified, we excluded 18 because of absence of pertinent data. We found 10 cases of cervical dysplasia in the remaining 61 patients, compared to 2 in 49 non-exposed patients (P < 0.04). Comparison of the two groups revealed no difference in: mean years of disease duration, months of follow-up and age. The non-exposed patients were more likely to be on estrogen and hydroxychloroquine but less often on steroids and azathioprine. The study group with and without dysplasia were assessed; we found no difference in the mean, or total IV-C dose, smoking and estrogen use. There was a significant decrease in time to dysplasia in those, given IV-C, with previous dysplasia compared to those without.

These preliminary data suggests that IV-C causes an increased number of abnormal Papanicolaou (Pap) smears in SLE patients, particularly those with previous dysplasia.

Key Words: SLE • cervical dysplasia • intravenous cyclosphosphamide

Lupus, Vol. 9, No. 7, 542-544 (2000)
DOI: 10.1177/096120330000900711


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Gayed, S Bernatsky, R Ramsey-Goldman, A. Clarke, and C Gordon Lupus and cancer Lupus, May 1, 2009; 18(6): 479 - 485. [Abstract] [PDF]

				S. Bernatsky, M. Hudson, J. Pope, J. Markland, D. Robinson, N. Jones, P. Docherty, M. Abu-Hakima, S. LeClerc, J. Dunne, et al. Reports of abnormal cervical cancer screening tests in systemic sclerosis Rheumatology, February 1, 2009; 48(2): 149 - 151. [Abstract] [Full Text] [PDF]

				M.V. Febronio, R.M.R. Pereira, E. Bonfa, A.D. Takiuti, E.A.G. Pereyra, and C.A.A. Silva Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 430 - 435. [Abstract] [PDF]

				S. Bernatsky, R. Ramsey-Goldman, C. Gordon, L. Joseph, J.-F. Boivin, R. Rajan, A. Allen, A. D. Moore, M.-H. Leung, and A. Clarke Factors associated with abnormal Pap results in systemic lupus erythematosus Rheumatology, November 1, 2004; 43(11): 1386 - 1389. [Abstract] [Full Text] [PDF]

				M Petri Cyclophosphamide: new approaches for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 366 - 371. [Abstract] [PDF]

				R Ramsey-Goldman and A E Clarke Double trouble: are lupus and malignancy associated? Lupus, June 1, 2001; 10(6): 388 - 391. [PDF]